Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL2039 Target Snapshot

Amine oxidase [flavin-containing] B · SINGLE PROTEIN · Homo sapiens

Back to Search Search this target Browse approvals Evidence Card
7,773Compounds
1,491Assays
36Approved Drugs
9,694.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Research home Demo workspace
Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-14

Amine oxidase [flavin-containing] B shows approved-linked disease relevance led by Parkinson disease. 5 more disease programs remain visible in the same review block. 5 linked drugs keep the current disease frame grounded. Protein identity stays anchored to UniProt P27338. Start with Parkinson disease, then reuse UniProt P27338 as the stable protein anchor across project notes and exports.

Review focus
Review-ready target frame

Start with Parkinson disease, then reuse UniProt P27338 as the stable protein anchor across project notes and exports.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-14 5 linked drugs
Open source guide
Disease program
Parkinson disease

Amine oxidase [flavin-containing] B shows approved-linked disease relevance led by Parkinson disease. 5 more disease programs remain visible in the same review block. 5 linked drugs remain visible in the same block.

Start review with Parkinson disease because it currently carries approved-linked support. Linked drugs include RASAGILINE MESYLATE, RASAGILINE TARTRATE, SAFINAMIDE, SAFINAMIDE MESYLATE. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Disease source · ChEMBL drug mechanism + indication proxy
Approved-linked Open Targets-ready proxy 5 linked drugs
Open disease block
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Amine oxidase [flavin-containing] B as ChEMBL target CHEMBL2039, mapped to UniProt P27338. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Amine oxidase [flavin-containing] B
SINGLE PROTEIN · Homo sapiens
As of 2026-09-14
ChEMBL target ID
CHEMBL2039
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-14
www.ebi.ac.uk
UniProt accession
P27338
Amine oxidase [flavin-containing] B
UniProt accession via ChEMBL component mapping As of 2026-09-14
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-14
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether Amine oxidase [flavin-containing] B is the right protein anchor across sources, using UniProt P27338 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need to confirm why Parkinson disease is currently framed as approved-linked support. It currently carries 5 linked drugs in the same disease frame.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

Preferred NameAmine oxidase [flavin-containing] B
Target TypeSINGLE PROTEIN
OrganismHomo sapiens
UniProtP27338
ChEMBL ↗ UniProt ↗ NCBI Protein ↗

Next Actions

SearchRun a focused querySearch the database using this target name as the starting context. ApprovalsCheck approved moleculesSee which approved drugs connect back to this target and its surrounding signal space. FeedScan papers & updatesStay in the project thread while checking recent papers and platform updates.
UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelAmine oxidase [flavin-containing] B
UniProt AccessionP27338
Component TypeProtein
Sequence Length520 aa

Amine oxidase [flavin-containing] B

Source · UniProt accession via ChEMBL component mapping
UniProt Context ↗
Review Cue

How to read this target

Review this target as Amine oxidase [flavin-containing] B, mapped to UniProt P27338. Sequence length is 520 aa.

Mapped IDP27338
Review nameAmine oxidase [flavin-containing] B
OrganismHomo sapiens
Disease Relevance

Disease Relevance & Evidence Level

Open Targets-ready disease context using the current target-indication evidence contract.

Approved-linked Open Targets-ready proxy

Amine oxidase [flavin-containing] B shows approved-linked disease relevance led by Parkinson disease. 5 more disease programs remain visible in the same review block.

Approved-linked Approved
Parkinson disease
5 linked drugs · 5 direct · 5 efficacy
Linked drugRASAGILINE MESYLATE
Linked drugRASAGILINE TARTRATE
Linked drugSAFINAMIDE
Linked drugSAFINAMIDE MESYLATE
Approved-linked Approved
major depressive disorder
1 linked drug · 1 direct · 1 efficacy
Linked drugSELEGILINE
Late clinical Phase III
Borderline personality disorder
1 linked drug · 1 direct · 1 efficacy
Linked drugSELEGILINE
Late clinical Phase III
cocaine dependence
1 linked drug · 1 direct · 1 efficacy
Linked drugSELEGILINE
Late clinical Phase III
depressive disorder
1 linked drug · 1 direct · 1 efficacy
Linked drugSELEGILINE
Late clinical Phase III
pain
1 linked drug · 1 direct · 1 efficacy
Linked drugRALFINAMIDE
Source · ChEMBL drug mechanism + indication proxy
ChEMBL target record ↗
Review Cue

How to read disease relevance

Start review with Parkinson disease because it currently carries approved-linked support. Linked drugs include RASAGILINE MESYLATE, RASAGILINE TARTRATE, SAFINAMIDE, SAFINAMIDE MESYLATE. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Lead diseaseParkinson disease
Strongest levelApproved-linked
Block modeOpen Targets-ready proxy
Clinical Profile

Clinical Phase Distribution

36
Approved
6
Phase III
22
Phase II
2
Phase I
Assay Mix

Activity Type Distribution

IC508,649.0
KI948.0
EC5088.0
KD9.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL348961 10.85 IC50 0.014 Preclinical
CHEMBL972 10.77 IC50 0.017 Approved
CHEMBL2333930 9.89 Ki 0.129 Preclinical
CHEMBL4129303 9.87 IC50 0.134 Preclinical
CHEMBL3319256 9.77 Ki 0.17 Preclinical
CHEMBL3319268 9.64 IC50 0.227 Preclinical
CHEMBL3319244 9.59 Ki 0.26 Preclinical
CHEMBL3319272 9.57 Ki 0.27 Preclinical
CHEMBL1642678 9.55 Ki 0.28 Preclinical
CHEMBL3319247 9.54 Ki 0.29 Preclinical
Distribution

pChEMBL Value Distribution

1015
5.0
805
5.5
756
6.0
648
6.5
583
7.0
433
7.5
289
8.0
143
8.5
54
9.0
18
9.5
pChEMBL
Approved Drugs

Approved Drugs

SAFINAMIDE
CHEMBL396778
Approved 2015
Properties Compare Identifier
ISTRADEFYLLINE
CHEMBL431770
Approved 2013
Properties Compare Identifier
RASAGILINE
CHEMBL887
Approved 2005
Properties Compare Identifier
RASAGILINE MESYLATE
CHEMBL1201142
Approved 2005
Properties Compare Identifier
LINEZOLID
CHEMBL126
Approved 2000
Properties Compare Identifier
PIOGLITAZONE
CHEMBL595
Approved 1999
Properties Compare Identifier
ROSIGLITAZONE
CHEMBL121
Approved 1999
Properties Compare Identifier
SELEGILINE
CHEMBL972
Approved 1989
Properties Compare Identifier
SELEGILINE HYDROCHLORIDE
CHEMBL1200904
Approved 1989
Properties Compare Identifier
PARGYLINE
CHEMBL673
Approved 1982
Properties Compare Identifier
MENADIONE
CHEMBL590
Approved 1982
Properties Compare Identifier
TRANYLCYPROMINE
CHEMBL3989843
Approved 1961
Properties Compare Identifier
PHENELZINE
CHEMBL1089
Approved 1961
Properties Compare Identifier
Assay Landscape

Assay Landscape

1,491
Total Assays
5,042
Tested Compounds
4
Assay Types
Binding — 1,462 assays, 5,042 compounds
BAO Format Assays Compounds Avg pChEMBL
single protein format 884 2,796 5.9
cell-based format 403 1,879 6.2
assay format 125 263 6.1
microsome format 19 93 6.7
tissue-based format 16 10 8.2
organism-based format 14 0 —
mitochondrion format 1 1 6.6
ADME — 13 assays, 35 compounds
BAO Format Assays Compounds Avg pChEMBL
single protein format 11 33 5.6
cell-based format 2 2 5.8
Functional — 10 assays, 0 compounds
BAO Format Assays Compounds Avg pChEMBL
assay format 10 0 —
Toxicity — 6 assays, 12 compounds
BAO Format Assays Compounds Avg pChEMBL
assay format 6 12 5.0

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine